Revelation Biosciences, Inc.
REVB
$3.40
$0.061.80%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.35% | -4.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.77% | 32.61% | |||
| Operating Income | 28.77% | -32.61% | |||
| Income Before Tax | 73.28% | -212.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 73.28% | -212.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 73.28% | -212.89% | |||
| EBIT | 28.77% | -32.61% | |||
| EBITDA | 28.85% | -32.67% | |||
| EPS Basic | 83.70% | -108.53% | |||
| Normalized Basic EPS | 83.70% | -108.53% | |||
| EPS Diluted | 83.63% | -108.53% | |||
| Normalized Diluted EPS | 83.70% | -108.53% | |||
| Average Basic Shares Outstanding | 63.89% | 50.05% | |||
| Average Diluted Shares Outstanding | 63.89% | 50.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
